PI3K/AKT/mTOR pathway blockade with pan-PI3K/mTORC1/2 inhibition produced substantial PFS gains in PIK3CA wild-type disease, addressing an unmet need after CDK4/6 plus endocrine resistance. Adding ...

Wortmannin（渥曼青霉素，AbMole，M2053）是一种源自真菌的甾体代谢物，作为磷脂酰肌醇3-激酶（PI3K）家族的强效共价抑制剂，能不可逆地结合PI3K催化亚基。Wortmannin还能抑制同属PI3K家族的DNA依赖性蛋白激酶（DNA-PK）和共济失调毛细血管扩张症突变激酶（ATM）。在生物学活性上，Wortmannin（渥曼青霉素，AbMole，M2053） ...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...

A new experimental drug, Nerandomilast, has shown potential in reducing lung inflammation and fibrosis in preclinical models of Idiopathic Inflammatory Myopathy–Associated Interstitial Lung Disease ...

Restoring the gut microbiota through fecal microbiota transplantation reversed these effects. The treatment replenished CX3CR1-positive NK cells, reduced lung damage, and improved survival. Targeted ...

Sepsis and severe pneumonia are frequently accompanied by disruption of the gut microbiota, leading to immune dysfunction and ...

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — Hong Kong, Shanghai & Florham Park, NJ ...

CEO and co-founder Brian Sullivan outlined the company’s clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD Cowen’s 46th Annual ...

Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] ...

TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM ESTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

FAYETTEVILLE, GA, UNITED STATES, March 10, 2026 /EINPresswire.com/ -- Chronic diabetic wounds fail to heal because ...